TOKYO, Japan I November 28, 2014 I Nippon Kayaku Co., Ltd. (Head Office: Tokyo; President: Akira Mandai; hereafter referred to as “Nippon Kayaku”) today launches the sale of Infliximab BS for I.V. Infusion 100mg “NK”.
Infliximab BS for I.V. Infusion 100mg “NK” is an Infliximab (genetic recombination) biosimilar drug that plays an important role in treatment of rheumatoid arthritis, inflammatory bowel disease, and other autoimmune diseases. Already marketed in 29 countries including South Korea and parts of Europe, Infliximab BS is the first monoclonal antibody biosimilar to be approved in Japan. Nippon Kayaku began development of Infliximab BS in November 2010 following the conclusion of an agreement with the Celltrion Group (Head Office: Incheon, South Korea, CEO & Chairman: Jung Jin Seo) for joint development and marketing in Japan. The drug received approval in July 2014.
Infliximab BS for I.V. Infusion 100mg “NK” is the second biosimilar for Nippon Kayaku following the FILGRASTIM BS Inj. Syringe “NK” first marketed last year. In the field of autoimmune diseases, since 2001 Nippon Kayaku has marketed SALIGREN® Capsule 30mg, a drug for the treatment of dry-mouth symptoms among patients suffering from Sjögren’s syndrome. With the marketing of Infliximab BS for I.V. Infusion 100mg “NK”, we expect to make an even greater contribution to the patients, families, medical professionals dealing with rheumatoid arthritis and inflammatory bowel disease.
[Reference material – Profile of Celltrion, Inc.]
| Company name |
Celltrion, Inc. |
| Location |
Incheon, South Korea |
| Listed on |
KOSDAQ |
| Business areas |
Headquartered in Incheon, Korea, Celltrion Group is a leading biopharmaceutical company, specializing in monoclonal antibody biosimilars and novel biopharmaceuticals. Celltrion focuses on the development of high quality biosimilars and antibody therapeutics that treat various viral diseases such as pandemic/seasonal influenzas and rabies, and is planning for the launching of their biosimilar drugs starting in 2012.
Celltrion Healthcare conducts the marketing and sales activities for the distribution of Celltrion’s biopharmaceutical products. |
| Link |
http://www.celltrion.com/ |
SOURCE: Nippon Kayaku
Post Views: 41
TOKYO, Japan I November 28, 2014 I Nippon Kayaku Co., Ltd. (Head Office: Tokyo; President: Akira Mandai; hereafter referred to as “Nippon Kayaku”) today launches the sale of Infliximab BS for I.V. Infusion 100mg “NK”.
Infliximab BS for I.V. Infusion 100mg “NK” is an Infliximab (genetic recombination) biosimilar drug that plays an important role in treatment of rheumatoid arthritis, inflammatory bowel disease, and other autoimmune diseases. Already marketed in 29 countries including South Korea and parts of Europe, Infliximab BS is the first monoclonal antibody biosimilar to be approved in Japan. Nippon Kayaku began development of Infliximab BS in November 2010 following the conclusion of an agreement with the Celltrion Group (Head Office: Incheon, South Korea, CEO & Chairman: Jung Jin Seo) for joint development and marketing in Japan. The drug received approval in July 2014.
Infliximab BS for I.V. Infusion 100mg “NK” is the second biosimilar for Nippon Kayaku following the FILGRASTIM BS Inj. Syringe “NK” first marketed last year. In the field of autoimmune diseases, since 2001 Nippon Kayaku has marketed SALIGREN® Capsule 30mg, a drug for the treatment of dry-mouth symptoms among patients suffering from Sjögren’s syndrome. With the marketing of Infliximab BS for I.V. Infusion 100mg “NK”, we expect to make an even greater contribution to the patients, families, medical professionals dealing with rheumatoid arthritis and inflammatory bowel disease.
[Reference material – Profile of Celltrion, Inc.]
| Company name |
Celltrion, Inc. |
| Location |
Incheon, South Korea |
| Listed on |
KOSDAQ |
| Business areas |
Headquartered in Incheon, Korea, Celltrion Group is a leading biopharmaceutical company, specializing in monoclonal antibody biosimilars and novel biopharmaceuticals. Celltrion focuses on the development of high quality biosimilars and antibody therapeutics that treat various viral diseases such as pandemic/seasonal influenzas and rabies, and is planning for the launching of their biosimilar drugs starting in 2012.
Celltrion Healthcare conducts the marketing and sales activities for the distribution of Celltrion’s biopharmaceutical products. |
| Link |
http://www.celltrion.com/ |
SOURCE: Nippon Kayaku
Post Views: 41
